Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity.

ABSTRACT: Anthracycline-induced cardiotoxicity (AIC) poses a clinical challenge in the management of cancer patients. AIC is characterized by myocardial systolic dysfunction and remodeling, caused by cardiomyocyte DNA damage, oxidative stress, mitochondrial dysfunction, or renin-angiotensin-aldosterone system (RAAS) dysregulation. In the past decade, after positive results of a PARADIGM-HF trial, a new class of drugs, namely angiotensin receptor/neprilysin inhibitors (ARNi), was incorporated into the management of patients with heart failure with reduced ejection fraction. As demonstrated in a variety of preclinical studies of cardiovascular diseases, the cardioprotective effects of ARNi administration are associated with decreased oxidative stress levels, the inhibition of myocardial inflammatory r

SUBMITTER: Sobiborowicz-Sadowska AM 

PROVIDER: S-EPMC9818213 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature